MERS CoV News and Research

RSS

In recent history, we have witnessed the emergence of several different life-threatening viruses. In addition to causing serious public health concerns around the globe, they have been responsible for significant human morbidity and mortality. Modern life that entails uncurtailed travel of humans and goods means that initially localized outbreaks may pose a risk of transmission anywhere in the world.

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Further confirmation Holder pasteurization inactivates SARS-CoV-2 in breast milk

Researchers in Australia have shown that a standard pasteurization method commonly used in human milk banks is effective at inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Jun 2020

Direct structural link between SARS-CoV-2 and essential fatty acid

Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.

21 Jun 2020

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

By performing a genome-wide CRISPR screen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), U.S. researchers identified novel proviral genes and pathways, and highlighted host genes that may regulate coronavirus disease (COVID-19) pathogenesis, as well as revealing potential targets for novel treatment approaches. Their findings are currently available on the bioRxiv* preprint server.

18 Jun 2020

Highly conserved RNA structures are essential for SARS-CoV-2 replication and pathogenesis

A recent study from the University of North Carolina at Chapel Hill revealed how selective pressure helps in preserving secondary RNA structures in coronavirus genomes, unveiling a pivotal role of these elements in viral replication and pathogenesis. The paper is currently available on the bioRxiv* preprint server.

17 Jun 2020

Antibiotic X-206 effective against SARS-CoV-2 in vitro

The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.

16 Jun 2020

How antibodies neutralize SARS-CoV-2 in convalescent patients

A new study by researchers from the United Kingdom and Taiwan and published on the preprint server bioRxiv in June 2020 describes the structural basis for the neutralizing effect of the SARS-CoV-2 antibody on the virus. This also indicates a possible therapeutic molecule by identifying its binding epitope as possibly a major neutralizing site.

16 Jun 2020

Researchers receive federal funding to rapidly repurpose FDA-approved drugs for COVID-19

Researchers at the University of Maryland School of Medicine will be partnering on an agreement funded by the federal government's Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19.

16 Jun 2020

Study reports structure of enzyme activator for high pathogenic avian influenza

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the current pandemic of COVID-19, is the focus of many investigators seeking to find an effective vaccine or therapeutic. Among the potential targets are various protease enzymes suspected of allowing the virus to gain entry to host cells and establish a successful infection.

16 Jun 2020

NIAID and Moderna scientists describe SARS-CoV-2 vaccine development

Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.

14 Jun 2020

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020

COVID-19 likely to be a seasonal disease

A study conducted in Sydney during the early epidemic stage of COVID-19 has found an association between lower humidity and an increase in locally acquired positive cases. Researchers discovered a 1 percent decrease in humidity could increase the number of COVID-19 cases by 6 percent.

1 Jun 2020

How COVID-19 affects the nervous system

A new paper published in the journal JAMA Neurology in May 2020 discusses the presentation and complications of COVID-19 with respect to the nervous system.

31 May 2020

Anosmia and changes in brain MRI in COVID-19

Even as the COVID-19 pandemic was sweeping across the world, new symptoms and clinical presentations appeared, often confusing the picture. A case report from Italy, published in the journal JAMA Neurology in May 2020, shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be a neurotropic virus, and may cause infection to present primarily with anosmia.

31 May 2020

Researchers review all clinical and research findings related to COVID-19

Due to the devastating worldwide impact of COVID-19, the illness caused by the SARS-CoV-2 virus, there has been unprecedented efforts by clinicians and researchers from around the world to quickly develop safe and effective treatments and vaccines.

29 May 2020

5-day Remdesivir dose works as well as the 10-day dose in COVID-19, study finds

With more than 5.8 million people infected with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the search is on for an effective SARS-CoV-2 vaccine or drug to treat COVID-19 disease.

28 May 2020

Genomic variation and descent of SARS-CoV-2 strains in India

The pandemic of COVID-19 that is still affecting over 188 countries and territories the world over has taken over 359,000 lives in just under five months, while affecting at least 5.8 million people. Different strains have diverged from the original strain detected in Wuhan, China.

28 May 2020

Neurological complications of COVID-19: What is known so far?

Researchers at the São Leopoldo Mandic School of Medicine in Brazil have presented a review of the current data available on the neurological effects of coronavirus disease 2019 (COVID-9).

27 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020